急性リンパ・リンパ芽球性白血病治療の世界市場2014-2025:治療別(化学療法、ハイパーCVAD、リンカーレジメン、標的療法、放射線療法)

◆英語タイトル:Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis By Therapy (Chemotherapy, Hyper-CVAD, Linker Regimen, Targeted Therapy, Radiation Therapy), And Segment Forecasts, 2014 - 2025
◆商品コード:GVIEW801024
◆発行会社(調査会社):Grand View Research
◆発行日:2017年10月6日
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥874,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,094,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、急性リンパ・リンパ芽球性白血病治療の世界市場について調査・分析し、急性リンパ・リンパ芽球性白血病治療の世界市場動向、急性リンパ・リンパ芽球性白血病治療の世界市場規模、市場予測、セグメント別急性リンパ・リンパ芽球性白血病治療市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.
Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Further Key Findings From the Report Suggest:

• Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products

• Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery

• Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes

• North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region

• Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region

• Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation

• Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies

【レポートの目次】

Table of Content

Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region-wise market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Acute lymphocytic/lymphoblastic leukemia therapeutics market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising incidences of acute lymphoblastic leukemia
3.2.2 Technological advancements
3.2.3 Increasing initiatives from public and private organizations
3.2.4 Increasing preference over targeted therapies
3.3 Market Restraint Analysis
3.3.1 Regulatory issues and patent expiry of blockbuster drugs
3.4 Penetration & growth prospect mapping
3.5 Acute lymphoblastic leukemia therapeutic market – SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis – Porter’s
3.7 Company Market Share, 2016
Chapter 4 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product Estimates & Trend Analysis
4.1 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market, 2014 – 2025 (USD Million)
4.2.2 Hyper-CVAD
4.2.2.1 Hyper-CVAD market, 2014 – 2025 (USD Million)
4.2.3 CALGB 8811 regimen
4.2.3.1 CALGB 8811 regimen market, 2014 – 2025 (USD Million)
4.2.4 Linker regimen
4.2.4.1 Linker regimen market, 2014 – 2025 (USD Million)
4.2.5 Nucleoside Metabolic Inhibitors
4.2.5.1 Nucleoside Metabolic Inhibitors market, 2014 – 2025 (USD Million)
4.2.6 Oncaspar
4.2.6.1 Oncaspar market, 2014 – 2025 (USD Million)
4.3 Targeted Therapy
4.3.1 Targeted therapy market, 2014 – 2025 (USD Million)
4.4 Radiation Therapy
4.4.1 Radiation therapy market, 2014 – 2025 (USD Million)
4.5 Stem cell transplantation
4.5.1 Stem cell transplantation market, 2014 – 2025 (USD Million)
Chapter 5 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Type Estimates & Trend Analysis
5.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Type Movement Analysis
5.2 Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
5.2.1 Philadelphia chromosome market, 2014 – 2025 (USD Million)
5.3 Precursor B-cell ALL
5.3.1 Precursor B-cell ALL market, 2014 – 2025 (USD Million)
5.4 T-cell ALL
5.4.1 T-cell ALL market, 2014 – 2025 (USD Million)
Chapter 6 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Regional Estimates & Trend Analysis, by Product
6.1 Acute lymphocytic/ lymphoblastic leukemia therapeutics market share by region, 2016 & 2025
6.2 North America
6.2.1 North America acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.3 Europe
6.3.1 Europe acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.3.4 France
6.3.4.1 France acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.4.3 China
6.4.3.1 China acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.4.4 India
6.4.4.1 India acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.6 MEA
6.6.1 MEA acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 – 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Erytech Pharma.
7.3.1.1 Company overview
7.3.1.2 Financial Performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Spectrum Pharmaceuticals Inc.
7.3.2.1 Company overview
7.3.2.2 Financial Performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Genmab A/S
7.3.3.1 Company overview
7.3.3.2 Financial Performances
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Bristol-Myers Squibb Company
7.3.4.1 Company overview
7.3.4.2 Financial Performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Genzyme Corporation (Sanofi)
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Pfizer, Inc.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Sigma-tau spa
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Novartis AG
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Celgene Corporation
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 Juno Therapeutics, Inc.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 List of Secondary Sources
TABLE 3 North America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by therapy, 2014 - 2025 (USD million)
TABLE 4 North America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 5 North America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 6 U.S. acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 7 U.S. acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 8 U.S. acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 9 Canada acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 10 Canada acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 11 Canada acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 12 Europe acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 13 Europe acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 14 Europe acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 15 UK acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 16 UK acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 17 UK acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 18 Germany acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 19 Germany acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 20 Germany acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 21 France acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 22 France acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 23 France acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 24 Asia Pacific acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 25 Asia Pacific acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 26 Asia Pacific acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 27 Japan acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 28 Japan acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 29 Japan acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 30 China acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 31 China acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 32 China acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 33 India acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 34 India acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 35 India acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 36 Latin America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 37 Latin America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 38 Latin America acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 39 Brazil acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 40 Brazil acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 41 Brazil acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 42 Mexico acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 43 Mexico acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 44 Mexico acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 45 MEA acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 46 MEA acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 47 MEA acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 48 South Africa acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 49 South Africa acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by chemotherapy, 2014 - 2025 (USD million)
TABLE 50 South Africa acute lymphocytic/ lymphoblastic leukemia therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD million)
TABLE 51 Company Analysis

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends &outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Company share analysis, 2016
FIG. 10 Acute lymphocytic/lymphoblastic leukemia therapeutics market product outlook: key takeaways
FIG. 11 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product movement analysis
FIG. 12 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 13 Hyper-CVAD market, 2014 - 2025 (USD Million)
FIG. 14 CALGB 8811 regimen market, 2014 - 2025 (USD Million)
FIG. 15 Linker regimen market, 2014 - 2025 (USD Million)
FIG. 16 Nucleoside Metabolic Inhibitors market, 2014 - 2025 (USD Million)
FIG. 17 Oncaspar market, 2014 - 2025 (USD Million)
FIG. 18 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 19 Radiation market, 2014 - 2025 (USD Million)
FIG. 20 Stem cell transplantation market, 2014 - 2025 (USD Million)
FIG. 21 Acute lymphocytic/ lymphoblastic leukemia therapeutics market distribution channel outlook: key takeaways
FIG. 22 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Distribution channel movement analysis
FIG. 23 Philadelphia chromosome market, 2014 - 2025 (USD Million)
FIG. 24 Precursor B-cell ALL market, 2014 - 2025 (USD Million)
FIG. 25 T-cell ALL market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2016 & 2025
FIG. 28 North America acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 U.S. acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Canada acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 Europe acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 UK acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Germany acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 France acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 Asia Pacific acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 Japan acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 China acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 India acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Latin America acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Brazil acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 Mexico acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 MEA acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 South Africa acute lymphocytic/ lymphoblastic leukemia therapeutics market, 2014 - 2025 (USD Million)
FIG. 44 Strategy framework
FIG. 45 Participant categorization

★調査レポート[急性リンパ・リンパ芽球性白血病治療の世界市場2014-2025:治療別(化学療法、ハイパーCVAD、リンカーレジメン、標的療法、放射線療法)] (コード:GVIEW801024)販売に関する免責事項を必ずご確認ください。
★調査レポート[急性リンパ・リンパ芽球性白血病治療の世界市場2014-2025:治療別(化学療法、ハイパーCVAD、リンカーレジメン、標的療法、放射線療法)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆